Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases
The present invention provides substituted pyrido[2,3-d]pyrimidine compounds useful as inhibitors of protein kinases, pharmaceutically acceptable compositions thereof, and methods of using the same.
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 2 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
6. A pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, carrier, or vehicle and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, carrier, or vehicle and a compound of claim 2 , or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, carrier, or vehicle and a compound of claim 3 , or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, carrier, or vehicle and a compound of claim 4 , or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising a pharmaceutically acceptable adjuvant, carrier, or vehicle and a compound of claim 5 , or a pharmaceutically acceptable salt thereof.
11. A method for inhibiting activity of fibroblast growth factor receptor 4, or a mutant thereof, in a patient or in a biological sample, comprising the step of administering to the patient or contacting the biological sample with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
12. A method for inhibiting activity of fibroblast growth factor receptor 4, or a mutant thereof, in a patient or in a biological sample, comprising the step of administering to the patient or contacting the biological sample with a compound of claim 2 , or a pharmaceutically acceptable salt thereof.
13. A method for inhibiting activity of fibroblast growth factor receptor 4, or a mutant thereof, in a patient or in a biological sample, comprising the step of administering to the patient or contacting the biological sample with a compound of claim 3 , or a pharmaceutically acceptable salt thereof.
14. A method for inhibiting activity of fibroblast growth factor receptor 4, or a mutant thereof, in a patient or in a biological sample, comprising the step of administering to the patient or contacting the biological sample with a compound of claim 4 , or a pharmaceutically acceptable salt thereof.
15. A method for inhibiting activity of fibroblast growth factor receptor 4, or a mutant thereof, in a patient or in a biological sample, comprising the step of administering to the patient or contacting the biological sample with a compound of claim 5 , or a pharmaceutically acceptable salt thereof.